Article

Stabilization of vaccines and antibiotics in silk and eliminating the cold chain.

Tufts University, Department of Biomedical Engineering, Medford, MA 02155, USA.
Proceedings of the National Academy of Sciences (Impact Factor: 9.81). 07/2012; 109(30):11981-6. DOI: 10.1073/pnas.1206210109
Source: PubMed

ABSTRACT Sensitive biological compounds, such as vaccines and antibiotics, traditionally require a time-dependent "cold chain" to maximize therapeutic activity. This flawed process results in billions of dollars worth of viable drug loss during shipping and storage, and severely limits distribution to developing nations with limited infrastructure. To address these major limitations, we demonstrate self-standing silk protein biomaterial matrices capable of stabilizing labile vaccines and antibiotics, even at temperatures up to 60 °C over more than 6 months. Initial insight into the mechanistic basis for these findings is provided. Importantly, these findings suggest a transformative approach to the cold chain to revolutionize the way many labile therapeutic drugs are stored and utilized throughout the world.

Download full-text

Full-text

Available from: Xiao Hu, Jul 07, 2015
1 Follower
 · 
127 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Herein, we describe the delivery of plasmid DNA (pDNA) using silk fibroin (SF) layer-by-layer assembled microcapsules. Deposition of fluorescently labeled SF onto polystyrene (PS) template particles resulted in increasing fluorescence intensity and decreasing surface charge in correlation to SF layer number. After removal of the PS core, hollow, monodisperse, and structurally stable SF microcapsules of variable size and shell thickness were obtained. Plasmid DNA encoding for enhanced green fluorescent protein (eGFP) was loaded onto 1 or 4 μm capsules, either by incorporation of pDNA within the innermost layer of the shell or by adsorption to the microcapsules surface, and in vitro pDNA release, cytotoxicty and eGFP expression were studied. Sustained pDNA release over 3 days was observed using both loading techniques, being accelerated in the presence of protease. DNA loaded SF microcapsules resulted in efficient cell transfection along with low cytotoxicity after 3 days incubation compared to treatment with pDNA/branched polyethylenimine complexes. Among the tested conditions highest transfection efficiencies were achieved using 1 μm capsules where pDNA was adsorbed to the capsule surface. Our results suggest that SF microcapsules are suitable for the localized delivery of pDNA, combining low cytotoxicity and high transfection efficiency.
    Biomaterials 06/2014; DOI:10.1016/j.biomaterials.2014.05.062 · 8.31 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Enabling innovation and access to health technologies remains a key strategy in combating infectious diseases in low- and middle-income countries (LMICs). However, a gulf between paying markets and the endemicity of such diseases has contributed to the dearth of R&D in meeting these public health needs. While the pharmaceutical industry views emerging economies as potential new markets, most of the world's poorest bottom billion now reside in middle-income countries--a fact that has complicated tiered access arrangements. However, product development partnerships--particularly those involving academic institutions and small firms--find commercial opportunities in pursuing even neglected diseases; and a growing pharmaceutical sector in BRICS countries offers hope for an indigenous base of innovation. Such innovation will be shaped by 1) access to building blocks of knowledge; 2) strategic use of intellectual property and innovative financing to meet public health goals; 3) collaborative norms of open innovation; and 4) alternative business models, some with a double bottom line. Facing such resource constraints, LMICs are poised to develop a new, more resource-effective model of innovation that holds exciting promise in meeting the needs of global health.
    Infectious Diseases of Poverty 01/2012; 1(1):2. DOI:10.1186/2049-9957-1-2 · 4.11 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Biomaterials of either natural or synthetic origin are used to fabricate implantable devices, as carriers for bioactive molecules or as substrates to facilitate tissue regeneration. For the design of medical devices it is fundamental to use materials characterized by non-immunogenicity, biocompatibility, slow and/or controllable biodegradability, non-toxicity, and structural integrity. The success of biomaterial-derived biodevices tends to be based on the biomimetic architecture of the materials. Recently, proteins from natural precursors that are essentially structural and functional polymers, have gained popularity as biomaterials. The silks produced by silkworms or spiders are of particular interest as versatile protein polymers. These form the basis for diverse biomedical applications that exploit their unique biochemical nature, biocompatibility and high mechanical strength. This review discusses and summarizes the latest advances in the engineering of silk-based biomaterials, focusing specifically on the fabrication of diverse bio-mimetic structures such as films, hydrogels, scaffolds, nanofibers and nanoparticles; their functionalization and potential for biomedical applications.
    Progress in Polymer Science 01/2013; 39(2). DOI:10.1016/j.progpolymsci.2013.09.002 · 26.85 Impact Factor